Literature DB >> 7857537

Spinal cord stimulation for the treatment of progressive systemic sclerosis and Raynaud's syndrome.

N Francaviglia1, C Silvestro, M Maiello, R Bragazzi, C Bernucci.   

Abstract

Progressive Systemic Scleroderma (PSS) is a generalized disease of connective tissue involving the skin, as well as other internal organs. The cutaneous signs are characterized by a progressive sclerosis and loss of function or dexterity in the hands. Between 1987 and 1992, 15 patients affected by scleroderma were treated by means of spinal cord stimulation (SCS) in order to reduce signs and symptoms related to vascular damage. The follow-up ranged from 12 months to 6 years. The study confirms that SCS is an effective therapy in patients with PSS and Raynaud's phenomenon because of its beneficial effects on the Raynaud episodes, ulcers, pain, vascular sclerosis and hand function. This method may have a primary role in the treatment of this chronic disorder because of the high probability of failure of other medical or surgical therapy.

Entities:  

Mesh:

Year:  1994        PMID: 7857537     DOI: 10.3109/02688699409002949

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  4 in total

1.  Intermediate-term follow-up of chronically ill patients with digital ischemia treated with peripheral digital sympathectomy.

Authors:  José R Soberón; Roy A Greengrass; William E Davis; Peter M Murray; Neil Feinglass
Journal:  Rheumatol Int       Date:  2016-02       Impact factor: 2.631

Review 2.  Spinal cord stimulation in cluster headache.

Authors:  Tilman Wolter; Holger Kaube
Journal:  Curr Pain Headache Rep       Date:  2013-04

Review 3.  Spinal cord stimulation for intractable chronic pain.

Authors:  Leonardo Kapural
Journal:  Curr Pain Headache Rep       Date:  2014-04

4.  Spinal cord stimulation for the treatment of pain and toe ulceration associated with systemic sclerosis: a case report.

Authors:  Hiroyuki Ito; Takafumi Tanei; Kyoko Sugawara; Yu Sando; Naohiro Hori
Journal:  Fukushima J Med Sci       Date:  2022-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.